Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial

Gonzalez, Henrik; Sunnerhagen, Katharina Stibrant; Sjöberg, Inger; Kaponides, Georgios; Olsson, Tomas; Borg, Kristian

doi:10.1016/s1474-4422(06)70447-1

Cited by 107 publications

(101 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29,30 The first study, a double-blind RCT, evaluated 142 patients with postpolio syndrome, most with severe weakness (Class IV or V based on the National Rehabilitation Postpolio Limb Classification). 29 The 2 primary outcome measures were improved strength of a muscle believed to be significantly affected by postpolio (25%-75% of normal for age and sex) and improved quality of life as measured by the Short Form-36. The study found a significant improvement of 8.6% in the strength of the most affected muscle, but this did not reach a predetermined target of 15% for clinical significance.…”

Section: Discussionmentioning

confidence: 99%

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]

et al. 2012

View full text Add to dashboard Cite

show abstract

“…TUG has been used to evaluate walking ability [21] and gait disturbance in iNPH patients [20]. The TUG measures the total time it takes a patient to perform a series of movements or, sitting in an armchair, to stand up, walk forward 3 m and return to the seated position.…”

Section: Methodsmentioning

confidence: 99%

Association between Milder Brain Deformation before a Shunt Operation and Improvement in Cognition and Gait in Idiopathic Normal Pressure Hydrocephalus

Yamamoto¹,

Kazui²,

Wada³

et al. 2013

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

We investigated the association between the degree of deformation of the brain before shunt operation and improvement of gait and cognitive impairment after shunt operation in 16 patients with idiopathic normal pressure hydrocephalus (iNPH). We evaluated gait and cognitive impairment and measured the cerebrospinal fluid volume in the ventricles/sylvian fissure (vVS) and the subarachnoid space at high convexity/midline areas (vHCM) using MR images with voxel-based morphometry before and 3 months after shunt operation. We used the ratio of vVS to vHCM (vVS/vHCM) as an index of the severity of brain deformation. After shunt operation, improvements were observed in gait, as shown by the Timed Up and Go (TUG) test and 10-meter reciprocating walking test (WT), and in cognitive function, as shown by the Mini-Mental State Examination, Alzheimer Disease Assessment Scale, Frontal Assessment battery (FAB), and Trail Making test A (TMT-A). The vVS/vHCM ratio was negatively correlated with improvement of the FAB, TMT-A and TUG. Preoperative vVS/vHCM was not significantly correlated with preoperative clinical assessments. The rate of change of vVS/vHCM was positively correlated with improvement in the WT. The improvements of gait and cognitive function were larger in iNPH patients with milder deformation of the brain before shunt operation.

show abstract

“…Following IVIG treatment, interferon-γ and tumor necrosis factor mRNA levels were reduced in the CSF, prompting a controlled trial performed in 135 patients. Although the results were essentially negative, some significant differences, of uncertain clinical importance, were observed in some physical activity and quality-of-life scores [91]. On this basis, a new FDA-approved multicenter clinical trial has started and is currently ongoing.…”

Section: Postpolio Syndromementioning

confidence: 99%

Efficacy of Intravenous Immunoglobulin in Neurological Diseases

2016

View full text Add to dashboard Cite

Owing to its anti-inflammatory efficacy in various autoimmune disease conditions, intravenous immunoglobulin (IVIG)-pooled IgG obtained from the plasma of several thousands individuals-has been used for nearly three decades and is proving to be efficient in a growing number of neurological diseases. IVIG therapy has been firmly established for the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, either as first-line therapy or adjunctive treatment. IVIG is also recommended as rescue therapy in patients with worsening myasthenia gravis and is beneficial as a second-line therapy for dermatomyositis and stiff-person syndrome. Subcutaneous rather than intravenous administration of IgG is gaining momentum because of its effectiveness in patients with primary immunodeficiency and the ease with which it can be administered independently from hospital-based infusions. The demand for IVIG therapy is growing, resulting in rising costs and supply shortages. Strategies to replace IVIG with recombinant products have been developed based on proposed mechanisms that confer the anti-inflammatory activity of IVIG, but their efficacy has not been tested in clinical trials. This review covers new developments in the immunobiology and clinical applications of IVIG in neurological diseases.

show abstract

Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial

Cited by 107 publications

References 38 publications

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]

Association between Milder Brain Deformation before a Shunt Operation and Improvement in Cognition and Gait in Idiopathic Normal Pressure Hydrocephalus

Efficacy of Intravenous Immunoglobulin in Neurological Diseases

Contact Info

Product

Resources

About